BLCO:NYE-Bausch + Lomb Corp (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 20.44

Change

-0.32 (-1.54)%

Market Cap

USD 7.32B

Volume

0.49M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.90 (-0.38%)

USD 68.65B
ALC Alcon AG

-1.24 (-1.31%)

USD 46.87B
RMD ResMed Inc

-1.38 (-0.56%)

USD 37.59B
BAX Baxter International Inc

-0.13 (-0.36%)

USD 18.36B
AVTR Avantor Inc

-0.06 (-0.27%)

USD 15.33B
ATR AptarGroup Inc

+0.33 (+0.20%)

USD 11.25B
TFX Teleflex Incorporated

-1.22 (-0.52%)

USD 11.21B
STVN Stevanato Group SpA

+0.08 (+0.43%)

USD 4.94B
WRBY Warby Parker Inc

+0.20 (+1.18%)

USD 2.09B
INFU InfuSystems Holdings Inc

-0.19 (-3.01%)

USD 0.15B

ETFs Containing BLCO

FSYD Fidelity Sustainable High.. 0.00 % 0.00 %

-0.34 (-0.70%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.81% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.81% 84% B 78% C+
Trailing 12 Months  
Capital Gain 23.73% 63% D 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.73% 63% D 64% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.54% 37% F 37% F
Dividend Return 0.54% 37% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.87% 95% A 72% C
Risk Adjusted Return 4.23% 32% F 25% F
Market Capitalization 7.32B 50% F 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector